Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
about
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Patient-reported outcomes from ...... alyses from the RA-BEAM study.
@en
type
label
Patient-reported outcomes from ...... alyses from the RA-BEAM study.
@en
prefLabel
Patient-reported outcomes from ...... alyses from the RA-BEAM study.
@en
P2093
P2860
P1476
Patient-reported outcomes from ...... alyses from the RA-BEAM study.
@en
P2093
Amy M DeLozier
Anna Dudek
Bruno Linetzky
Carol Gaich
Edward C Keystone
Jorge Velasco Zamora
Jose Arturo Covarrubias Cobos
Michael E Weinblatt
Peter C Taylor
Stephanie de Bono
P2860
P304
P356
10.1136/ANNRHEUMDIS-2017-211259
P407
P577
2017-08-10T00:00:00Z